Can a new infusion drug tame lung inflammation and cut steroid use?

NCT ID NCT06169397

ENROLLING_BY_INVITATION Disease control Sponsor: Xentria, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial is investigating whether an experimental drug called XTMAB-16 can safely control pulmonary sarcoidosis over the long term. The study includes people who have already completed a previous XTMAB-16 trial and are on a stable steroid dose. Researchers are monitoring side effects and checking whether the drug helps maintain or lower steroid use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called XTMAB-16 given as an infusion
What this could lead to: If successful, this could point toward a safer, long-term treatment option for pulmonary sarcoidosis that reduces reliance on steroids.
What could go wrong: This is an early-phase, open-label study with no placebo group, so results may not confirm effectiveness. Long-term safety data are still being collected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY SARCOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary sarcoidosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY SARCOIDOSIS

Contacts and locations

Locations

King's College Hospital NHS Foundation Trust

London, England, SE59RS, United Kingdom
NHS Tayside

Perth, Scotland, PH11NX, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust

Norwich, England, OX3 7LE, United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust

Coventry, England, CV22DX, United Kingdom
Xentria Investigative Site

Denver, Colorado, 80206, United States
Xentria Investigative Site

Chicago, Illinois, 60611, United States
Xentria Investigative Site

Greenville, North Carolina, 27858, United States
Xentria Investigative Site

Cincinnati, Ohio, 45267, United States
Xentria Investigative Site

Philadelphia, Pennsylvania, 19140, United States
Xentria Investigative Site

Prague, 140 59, Czechia
Xentria Investigative Site

Bielsk Podlaski, 15-044, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.